{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:08:56Z","timestamp":1790633336215,"version":"4.1.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec id=\"ab-hoi260017-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Timely diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is critical for early treatment to reduce morbidity and mortality, yet the timeliness of contemporary ATTR-CM diagnosis remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260017-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the time from incident heart failure (HF) diagnosis to ATTR-CM diagnosis and identify predictors of delayed diagnosis among Medicare beneficiaries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260017-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a cohort study using US Medicare fee-for-service data from January 2016 to December 2022. Medicare fee-for-service beneficiaries with HF and ATTR-CM were included. Data were analyzed from November 2024 to July 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260017-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>HF diagnosis with ATTR-CM diagnosis following HF diagnosis or within 1 year prior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260017-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was time to ATTR-CM diagnosis, measured as the number of days between each patient\u2019s first HF diagnosis and first ATTR-CM diagnosis. Multivariable logistic regression assessed demographic, clinical, and socioeconomic factors associated with delayed ATTR-CM diagnosis (defined as &amp;amp;gt;6 months from HF diagnosis to ATTR-CM diagnosis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260017-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 7770 patients with HF and ATTR-CM were identified in the Medicare dataset. The median (IQR) age at the time of ATTR-CM diagnosis was 81 (76-86) years; 5995 enrollees (77%) were men. The median (IQR) time from HF diagnosis to ATTR-CM diagnosis was 494 (63-1340) days. For the 6175 patients with a loop diuretic prescription before ATTR-CM diagnosis, the median (IQR) time between initial loop prescription and ATTR-CM diagnosis was 840 (252-1768) days. After adjustment, older age (odds ratio [OR], 0.68; 95% CI, 0.63-0.74), history of atrial fibrillation (OR, 0.39; 95% CI, 0.33-0.49), and carpal tunnel syndrome (OR, 0.85; 95% CI, 0.74-0.97) were associated with lower odds of delayed diagnosis. Female sex (OR, 1.28; 95% CI, 1.13-1.45), a history of aortic stenosis (OR 1.39; 95% CI, 1.20-1.62), chronic obstructive pulmonary disease (OR, 1.18; 95% CI, 1.03-1.34), coronary artery disease (OR, 1.26; 95% CI, 1.13-1.40), diabetes (OR, 1.21; 95% CI, 1.07-1.37), and hypertension (OR, 1.28; 95% CI, 1.13-1.45) were associated with higher odds of delayed diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260017-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>There were substantial delays between incident HF and diagnosis of ATTR-CM found in this study. Female sex and having a history of aortic stenosis, coronary artery disease, diabetes, hypertension, or chronic obstructive pulmonary disease, which are each associated with cardiomyopathy and breathlessness, were associated with delayed diagnosis. These findings highlight the need for a heightened index of suspicion for ATTR-CM in patients with other possible etiologies of cardiomyopathy or HF symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.0833","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:30:45Z","timestamp":1777476645000},"page":"524","source":"Crossref","is-referenced-by-count":7,"title":["Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population"],"prefix":"10.1001","volume":"11","author":[{"given":"Gabriela","family":"Spencer-Bonilla","sequence":"first","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fan","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Din","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Davies","sequence":"additional","affiliation":[{"name":"US Medical Affairs, BioPharmaceutical Medical, AstraZeneca, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia A.","family":"Papas","sequence":"additional","affiliation":[{"name":"US Medical Affairs, BioPharmaceutical Medical, AstraZeneca, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Huang","sequence":"additional","affiliation":[{"name":"US Medical Affairs, BioPharmaceutical Medical, AstraZeneca, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Venditto","sequence":"additional","affiliation":[{"name":"US Medical Affairs, BioPharmaceutical Medical, AstraZeneca, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Alexander","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of California, Los Angeles"},{"name":"Greater Los Angeles VA Healthcare System, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"hoi260017r1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis.","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"1","key":"hoi260017r2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review.","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"issue":"8","key":"hoi260017r3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11936-019-0743-2","article-title":"Emerging therapies for transthyretin cardiac amyloidosis.","volume":"21","author":"Alexander","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"11","key":"hoi260017r4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi260017r5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis.","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi260017r6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi260017r7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jacc.2025.10.021","article-title":"Delayed diagnosis of transthyretin amyloid cardiomyopathy in the Veterans Health Administration.","volume":"87","author":"Spencer-Bonilla","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hoi260017r8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008538","article-title":"Disparity in the setting of incident heart failure diagnosis.","volume":"14","author":"Sandhu","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"8","key":"hoi260017r9","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.mayocp.2021.04.021","article-title":"Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis.","volume":"96","author":"Fumagalli","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"37","key":"hoi260017r10","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1093\/eurheartj\/ehae345","article-title":"Loop diuretic therapy with or without heart failure: impact on prognosis.","volume":"45","author":"Friday","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"hoi260017r11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010718","article-title":"Equity in the setting of heart failure diagnosis: an analysis of differences between and within clinician practices.","volume":"17","author":"Gupta","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"3","key":"hoi260017r12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jchf.2022.11.013","article-title":"Predictors of incident heart failure diagnosis setting: insights from the Veterans Affairs Healthcare System.","volume":"11","author":"Tisdale","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"24","key":"hoi260017r13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016502","article-title":"Association of diagnostic coding-based frailty and outcomes in patients with heart failure: a report from the Veterans Affairs Health System.","volume":"9","author":"Kohsaka","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"hoi260017r14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.7326\/M17-0767","article-title":"Concentration of potentially preventable spending among high-cost medicare subpopulations: an observational study.","volume":"167","author":"Figueroa","year":"2017","journal-title":"Ann Intern Med"},{"issue":"3","key":"hoi260017r15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study.","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"hoi260017r16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis.","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"hoi260017r17","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis.","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"issue":"1","key":"hoi260017r18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"22","key":"hoi260017r19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years.","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"hoi260017r20","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies.","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"hoi260017r21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"3","key":"hoi260017r22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"issue":"1","key":"hoi260017r23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis.","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"issue":"12","key":"hoi260017r24","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","article-title":"Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?","volume":"108","author":"Aus dem Siepen","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"hoi260017r25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis.","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"issue":"1","key":"hoi260017r26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0735-1097(20)31503-5","article-title":"Sex differences in the phenotype of transthyretin cardiac amyloidosis due to Val122Ile mutations: insights from non-invasive pressure-volume analysis.","volume":"27","author":"Batra","year":"2021","journal-title":"J Card Fail"},{"issue":"1","key":"hoi260017r27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jjcc.2021.10.007","article-title":"Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy.","volume":"79","author":"Takashio","year":"2022","journal-title":"J Cardiol"},{"issue":"2","key":"hoi260017r28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","article-title":"Sex differences in transthyretin cardiac amyloidosis.","volume":"29","author":"Aimo","year":"2024","journal-title":"Heart Fail Rev"},{"issue":"3","key":"hoi260017r29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40119-022-00265-7","article-title":"Sex differences in wild-type transthyretin amyloidosis: an analysis from the transthyretin amyloidosis outcomes survey (THAOS).","volume":"11","author":"Campbell","year":"2022","journal-title":"Cardiol Ther"},{"issue":"2","key":"hoi260017r30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.011714","article-title":"Understudied, under-recognized, underdiagnosed, and undertreated: sex-based disparities in cardiovascular medicine.","volume":"15","author":"Burgess","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"hoi260017r31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.14797\/mdcvj.1328","article-title":"Sex disparities in cardiovascular disease.","volume":"20","author":"Mahowald","year":"2024","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"38","key":"hoi260017r32","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi260017r33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis.","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"hoi260017r34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis.","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hoi260017r35","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ejhf.1756","article-title":"Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome.","volume":"22","author":"Nitsche","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hoi260017r36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaccao.2021.08.008","article-title":"Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly Indian population: a pilot study.","volume":"3","author":"Singal","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"2","key":"hoi260017r37","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/13506129.2022.2159369","article-title":"Cardiac amyloidosis remains significantly underdiagnosed in patients undergoing TAVR: analysis of national inpatient sample.","volume":"30","author":"Terentes-Printzios","year":"2023","journal-title":"Amyloid"},{"issue":"8","key":"hoi260017r38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement.","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"hoi260017r39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/01.CIR.0000078641.19365.4C","article-title":"Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance.","volume":"108","author":"McCrohon","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"hoi260017r40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.hlc.2021.12.014","article-title":"Missed opportunities in identifying cardiomyopathy aetiology prior to advanced heart failure therapy.","volume":"31","author":"Aiad","year":"2022","journal-title":"Heart Lung Circ"},{"issue":"24","key":"hoi260017r41","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2847925\/jamacardiology_spencerbonilla_2026_oi_260017_1780929853.08221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:00:33Z","timestamp":1781103633000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2847925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.0833","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}